In 2023, Werewolf Therapeutics, Inc. anticipated multiple catalysts as the company progress the company's two clinical stage programs, WTX-124 and WTX-330, through first in human testing and expect to share initial clinical data on the safety, tolerability, and preliminary efficacy of WTX-124 in the fourth quarter. Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in fourth quarter of 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 USD | +1.27% | +7.17% | +23.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.83% | 205M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- HOWL Stock
- News Werewolf Therapeutics, Inc.
- Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330